Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
Conditions
Type 2 Diabetes
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Central Research Associates, LLC dba Flourish Research, Birmingham, Alabama, United States
Hope Clinical Research, Canoga Park, California, United States
Ark Clinical Research, Long Beach, California, United States
Catalina Research Institute, LLC, Montclair, California, United States
Paradigm Clinical Research Centers, LLC, San Diego, California, United States
Southwest General Healthcare Center, Fort Myers, Florida, United States
Panax Clinical Research, Miami Lakes, Florida, United States
Flourish Research Orlando, Winter Park, Florida, United States
David Kavtaradze MD, Inc, Cordele, Georgia, United States
Excel Clinical Research, Las Vegas, Nevada, United States
Diabetes and Endocrinology Associates of Stark County, Canton, Ohio, United States
Elligo Health Research, Inc., Austin, Texas, United States
Zenos Clinical Research, Dallas, Texas, United States
Synergy Group Medical, Houston, Texas, United States
Epic Clinical Research, Lewisville, Texas, United States
Diabetes & Glandular Disease Clinic, P.A., San Antonio, Texas, United States
Burke Internal Medicine and Research, Burke, Virginia, United States